* To evaluate the rate of FluMist administration compared to other influenza vaccine use in the following pediatric populations:
* Children younger than 24 months of age
* Children 24-59 months of age with a claim associated with a diagnosis of asthma
* Children 24-59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
* Children 24-59 months of age with immunosuppression
* To describe, in children in the above populations who receive FluMist, the type and number of Emergency Room visits or hospitalizations associated with an insurance claim within 42 days of receiving FluMist
* To explore the rationale for FluMist immunization of pediatric populations that are excluded from recommended usage by characterizing the use in these populations
